Market Newsdesk

SAN FRANCISCO, Sept. 12, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP —a national plaintiffs’ rights law firm with a premier securities practice group—notifies investors in Cogent Communications Holdings, Inc. (NASDAQ: CCOI) of the upcoming September 21, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows Cogent’s recent Q2 2026 financial disclosures, which underscore ongoing operational contractions as the class action moves forward.

The firm encourages investors who suffered substantial losses to submit your losses now.  

Q2 2026 Results Highlight Persistent Top-Line Pressures

On Aug. 6, 2026, Cogent reported its financial results for the second quarter of 2026, revealing continued revenue softening across core segments. Service revenue dipped to $235.6 million (representing a sequential decline from Q1 2026 and a year-over-year contraction), accompanied by ongoing double-digit drops in off-net revenue and declining customer connections. These results follow a pattern of balance-sheet adjustments, asset sales, and dividend recalibrations that have drawn heightened scrutiny from the investment community.

Key Case Details:

Class Period: Feb. 29, 2024 – May 1, 2026
Lead Plaintiff Deadline: Sept. 21, 2026
Visit:www.hbsslaw.com/ccoi
Contact the Firm Now: [email protected]
                                        844-916-0895

About the Securities Class Action:

The lawsuit challenges the propriety of Cogent’s disclosures about its optical wavelength “backlog,” assurances that this metric was somehow an indicator of its expected growth and, by extension, its reasonably expected revenue growth and stock’s value.

The complaint alleges that Cogent’s wavelength backlog was an illusory touted measure and unlikely to ever convert to revenue, that large quantities of customers in the backlog were unable or unwilling to accept delivery even if Cogent was in a position to provision the wavelength in a timely manner and that, as a result, the company materially misrepresented customer demand for its optical wavelength services and the nature of its backlog.

Cracks in Cogent’s early Class Period narrative began to emerge on February 27, 2025. That day, Cogent reported disappointing Q4 and FY 2024 financial results and revealed a 20% sequential decline in its backlog and that it removed 1500 orders because many were over one year old. Surprised, the market sent the price of the stock steeply lower.

Then, on May 8, 2025, the company reported disappointing Q1 2025 results and said it had more installation capacity than orders ready to be installed. Management said, “we built a funnel of wavelength opportunities with no defined installation window […] [a]nd as expected, the majority of that funnel fell out.” The market’s reaction was similar to February.

In apparent recognition that investors lost faith in the wavelength backlog story, the company abruptly ceased providing backlog data on February 20, 2026, when it reported Q4 and FY 2025 results. Again, the market sent the price of Cogent shares steeply lower.

Finally, on May 4, 2026, Cogent reported its Q1 2026 results that again disappointed on wavelength revenue and customer connections. Management conceded “[o]n wavelength installs, we have seen a variety of customers pushing out their acceptance[]” and “[w]e actually provisioned more wavelengths in the quarter than we did in the previous quarter, but the customers did not accept them.”

Hagens Berman’s Investigation

“We’re focused on whether Cogent and its management intentionally promoted wavelength backlog and funnel as a way to misrepresent both the company’s actual ability to convert them to earned revenues and the real company-centric wavelength demand,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

What Can Investors Do?

If you invested in Cogent and have substantial losses, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Cogent case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Cogent should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

SAN FRANCISCO, Sept. 12, 2026 (GLOBE NEWSWIRE) — On September 10, 2026, investors in The Cooper Companies, Inc. (NASDAQ: COO) saw the price of their shares trade down $9.31 (-14.6%) after the company reported Q3 2026 financial results that included revelations of its U.S. channel inventory destocking along with other negative surprises. The stock’s move lower wiped out over $1.7 billion of the company’s market capitalization.

The revelations have prompted national shareholders rights firm Hagens Berman to open an investigation into whether The Cooper Companies was sufficiently transparent beforehand about its sales practices and, if not, whether it may have violated the securities laws.

The firm encourages Cooper investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm’s attorneys.

Visit:
www.hbsslaw.com/coo

Direct Contact Email:
[email protected]

Firm Telephone: 844-916-0895

The Cooper Companies (COO) Investigation

Cooper is a global medical device company with two reporting segments. The largest – CooperVision – manufactures and markets hydrogel lens products for contact lens wearers and accounted for roughly 67% of Cooper’s total consolidated sales in fiscal 2025.

The investigation is focused on the propriety of Cooper’s statements about the mechanics contributing to CooperVision’s revenue growth and its sustainability.

During Cooper’s June 4, 2026 Q2 2026 earnings call, management emphasized CooperVision’s “solid quarter, with revenues increasing 8%, or 4% organically” and guided for CooperVision full year organic revenue growth of 3.5% to 4.5%, emphasizing that “[f]or CooperVision […] [o]utside of Asia Pac, demand remains solid for premium products, including daily silicone hydrogel lenses as well as torics and multifocals.”

The next day, the price of Cooper shares traded almost 8% higher.

Investors received some troubling news on September 9, 2026, when the company reported its Q3 2026 financial results. In particular, Cooper’s management revealed “our legacy hydrogels were down double-digit across the board[,]” “the results in the Americas reflected CooperVision’s US channel inventory reductions[,]” and “[w]e expect CooperVision revenue of $692 million to $706 million down 2% to flat organically.”

In response to an analyst’s question during the earnings call about whether the entirety of the reduced guide for CooperVision revenue was inventory-related, CEO Albert White III said, “it’s all destock […] [m]eaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory.”

Another analyst expressed concern, asking “why are they destocking […] [d]id you guys have too much inventory in the channel from past efforts to kind of prop up numbers?”

The market did not take kindly to the developments and sent the price of Coopers shares down over 14% the next day to close at a 52-week low of $54.17, with several analysts reportedly downgrading their ratings and price targets.

“We’re focused on whether Cooper was sufficiently transparent to investors about its CooperVision sales strategies,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Cooper and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Cooper should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

SAN FRANCISCO, Sept. 12, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.

View our latest video summary of the allegations: youtu.be/rsW1-f8ARRs

Class Period: Aug. 1, 2025 – May 15, 2026
Lead Plaintiff Deadline: Sept. 14, 2026
Visit:www.hbsslaw.com/regn
Contact the Firm Now: [email protected]
                                        844-916-0895

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:

The litigation is focused on the propriety of Regeneron’s repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the “Study”).

The Study’s primary endpoint was progression-free survival (“PFS”) and Regeneron has characterized the combination as a “potential blockbuster.” “Events” – disease progression or death – determined the timing and statistical power of the primary PFS analysis.

The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study’s preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.

Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial’s achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are “because the test arms are performing well.”

The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that “t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months.”

One prominent analyst reportedly questioned whether the decision was made because, in contrast to management’s expressed confidence, the “underlying PFS benefit may be insufficient to show statistical significance.”

Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to “slow event rates,” occurred nearly six months ago, and was “submitted it to all the global regulatory authorities in November, December timeframe.”

Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the “trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS).”

“We’re focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn’t really there,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the suit.

If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Regeneron case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/082393d4-7bba-4e66-b05a-6662f775f5b1

NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed against Flotek Industries, Inc. (“Flotek” or the “Company”) (NYSE: FTK) on behalf of investors who purchased or otherwise acquired Flotek securities between August 3, 2026 and August 14, 2026, inclusive (the “Class Period”).

Investors who purchased Flotek shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 26, 2026.

PLEASE CLICK HERE TO SUBMIT YOUR TRADE AND CONTACT INFORMATION

On August 3, 2026, Flotek announced that it had been awarded a 10-year agreement to support a 400-megawatt natural gas-fired power generation project for the Puerto Rico Electric Power Authority (“PREPA”), intended to help address Puerto Rico’s ongoing energy crisis.

The filed complaint alleges that Flotek made materially false and/or misleading statements and failed to disclose material information concerning the PREPA project and the Company’s business prospects. Investors were not adequately informed of, among other things:

• Credible reasons to question the experience, organization, and financial capacity of the consortium parties involved in the PREPA power generation project;
• The resulting risk that revenue associated with the PREPA contract would not be realized; and
• The alleged impact of these issues on the Company’s positive statements concerning its business, operations, and prospects.

On August 17, 2026, at approximately 1:20 PM Eastern Daylight Time, Wolfpack Research published a report alleging that Flotek’s approximately $400 million PREPA contract, which the report stated represented approximately 57% of Flotek’s backlog, had been canceled.

Following the publication of the report, Flotek’s stock price declined $7.17 per share, or approximately 20%, to close at $28.66 per share on August 17, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Hyliion Holdings Corp. (NYSE: HYLN) (“Hyliion” or the “Company”), on behalf of all investors who purchases Hyliion shares between May 12, 2026 and June 23, 2026, inclusive (the “Class Period”).

Investors who purchased Hyliion shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 27, 2026.

The filed Complaint alleges that:

• On May 12, 2026, Hyliion announced a non-binding Letter of Intent (LOI) with VFG Holdings (“VFG”) involving up to 250 KARNO Cores / 50 MW of potential data-center power deployments over five years.
• The lawsuit alleges Hyliion presented the VFG relationship and its broader commercial pipeline more positively than was justified by the underlying facts.
• HYLN rose sharply after the May announcement.
• On June 23, 2026, Pelican Way Research published a report questioning whether VFG had the operational and financial substance to execute the proposed deal.
• On this news, the price of Hyliion stock fell $1.27, or 17.2%, on June 23, 2026, and declined an additional $1.18 per share, or 19.3%, on June 24, 2026, to close at $4.92 per share.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Innventure, Inc. (NASDAQ: INV). (“Innventure” or the “Company”), on behalf of all investors who purchased Innventure shares between November 17, 2025, and August 13, 2026, inclusive (the “Class Period”).

Investors who purchased Innventure shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 27, 2026.

The filed Complaint alleges that Innventure and its executives overstated the likelihood/value of Accelsius’s DarkNX data-center project and, consequently, overstated Accelsius’s expected 2026 revenue and cash flow. Innventure presented the DarkNX agreement as a major, transformative commercial opportunity, while allegedly failing to disclose information indicating that the project was unlikely to materialize.

On August 13, 2026, Innventure said it was suspending its previously communicated 2026 Accelsius revenue and cash-flow expectations. Its Form 10-Q filed with the U.S. Securities and Exchange Commission stated that the DarkNX deployment site was no longer available and the project had been removed from internal bookings.

On this news Innventure fell $1.98 per share, or 55%, from the closing price on August 12, 2026, of $3.60 per share, to close at $1.62 per share, on August 14, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: 
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Beta Bionics and have suffered losses, you may


CLICK HERE


to contact us. You may also contact Kaplan Fox by emailing


[email protected]


or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas insulin pump (“iLet”), an automated insulin delivery system. The complaint alleges that throughout the Class Period, Beta Bionics received thousands of complaints from iLet customers, including numerous reports of serious, life-threatening hypoglycemia caused by device malfunctions that required hospitalization to treat. The root cause of these malfunctions was allegedly iLet’s extremely aggressive dosing algorithm.

The truth was allegedly revealed through a series of disclosures starting on January 8, 2026 when Beta Bionics surprised investors with a miss on the key metric of new iLet patient starts, which was followed by a 37% one-day stock price decline. Finally, on February 24, 2026, the full truth was allegedly revealed when the U.S. Food and Drug Administration (the “FDA”) publicly released its warning letter detailing a litany of violations and Defendants’ failure to correct them, and contradicting months of Defendants’ public statements that all back-filed complaints were for entirely benign issues. According to the complaint, the warning letter made clear that Defendants’ prior interpretation of FDA reporting requirements had not been reasonable, and had excluded numerous serious patient incidents that clearly should have been reported.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/beta-bionics-nasdaq-bbnx-class-action-lawsuit-learn-more-now/

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DICK’s Sporting Goods, Inc. (“Dick’s Sporting Goods” or the “Company”) (NYSE: DKS) on behalf of investors that purchased or otherwise acquired Dick’s Sporting Goods common stock between September 8, 2025 and August 24, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Dick’s Sporting Goods and have suffered losses, you may


CLICK HERE


to contact us. You may also contact Kaplan Fox by emailing


[email protected]


or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On September 8, 2025, the first day of the Class Period, Dick’s Sporting Goods announced the completion of its acquisition of Foot Locker, Inc. (“Foot Locker”) for approximately $2.5 billion in cash and stock.

The complaint alleges that throughout the Class Period, Defendants misled investors regarding the Company’s acquisition of Foot Locker, touting the acquisition as a strategic opportunity to drive growth and profitability while assuring investors that Foot Locker’s longstanding inventory and promotional challenges had been resolved. In reality, according to the complaint, those problems persisted, as Foot Locker remained heavily dependent on legacy footwear products that were exposed to intensifying promotional pressures across the athletic footwear industry.

The truth was allegedly revealed to investors before markets opened on August 25, 2026, when Dick’s Sporting Goods reported disappointing second-quarter 2026 results, which included revenue of $1.73 billion from Foot Locker that fell well short of analysts’ estimates of $1.81 billion. Dick’s Sporting Goods also reduced its net sales guidance for full-year 2026 and disclosed that it expected Foot Locker’s proforma comparable sales to yield a range of negative 2.0% to 0.0% for the year—down from Dick’s prior forecast of 1.5% to 3% growth.

On this news, the price of Dick’s Sporting Goods stock fell $55.02 per share, or 30.68%, to close at $124.31 per share on August 25, 2026.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/dicks-sporting-goods-inc-class-action-lawsuit-learn-more-now/

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the third quarter of 2026.

This quarter, there are constituent changes within one of our indexes: KBW Nasdaq Regional Banking Index (Index Ticker: KRX)

These changes will be effective prior to the opening of business on Monday, September 21, 2026.

As part of this rebalancing, below are the component-level changes across impacted indices:

KBW Nasdaq Regional Banking Index (Index Ticker: KRX)

Add (1)

: Central Bancompany, Inc. (Nasdaq: CBC)

Several of the KBW Nasdaq indexes have tradable exchange‐traded funds licensed: KBW Nasdaq Bank Index (Index Ticker: BKX^SM, ETF Ticker: KBWB^SM); KBW Nasdaq Capital Markets Index (Index Ticker: KSX^SM); KBW Nasdaq Insurance Index (Index Ticker: KIX^SM); KBW Nasdaq Regional Banking Index (Index Ticker: KRX^SM); KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX^SM, ETF Ticker: KBWD^SM); KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX^SM, ETF Ticker: KBWY^SM); KBW Nasdaq Property and Casualty Insurance Index (Index Ticker: KPX^SM, ETF Ticker: KBWP^SM); KBW Nasdaq Global Bank Index (Index Ticker: GBKX^SM); KBW Nasdaq Financial Technology Index (Index Ticker: KFTX^SM, ETF Ticker: FTEK.LN^SM).

Not all of the listed securities may be suitable for retail investors; in addition, not all of the listed securities may be available to U.S. investors. European investors interested in FTEK LN can contact Invesco at https://etf.invesco.com/gb/private/en/product/invesco-kbw-nasdaq-fintech-ucits-etf-acc/trading-information. U.S. investors cannot buy or hold FTEK LN. An investor cannot invest directly in an index.

About KBW

KBW (Keefe, Bruyette & Woods, Inc., operating in the U.S., and Stifel Nicolaus Europe Limited, also trading as Keefe, Bruyette & Woods Europe, operating in Europe) is a Stifel company. Over the years, KBW has established itself as a leading independent authority in the banking, insurance, brokerage, asset management, mortgage banking and specialty finance sectors. Founded in 1962, the firm maintains industry‐leading positions in the areas of research, corporate finance, mergers and acquisitions as well as sales and trading in equities securities of financial services companies.

Media Contact

Neil Shapiro, (212) 271-3447
[email protected]